Monney Marine, Mavromati Maria, Leboulleux Sophie, Gariani Karim
Endocr Connect. 2025 Mar 21;14(5). doi: 10.1530/EC-24-0529. Print 2025 May 1.
Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age. This condition is associated with various hormonal, reproductive and metabolic alterations, including androgen excess, ovulatory disorders and a hyperinsulinemic state. A personalized therapeutic approach is necessary to improve PCOS, focusing on patients' main concerns, with the goal of addressing ovarian dysfunction, reducing hyperandrogenism and improving metabolic alterations, particularly through weight reduction. The therapeutic class of glucagon-like peptide-1 receptor analogues (GLP-1 RAs) represents an attractive option for PCOS due to its various beneficial effects, such as weight loss. In this review, we discuss the clinical and pathological aspects of PCOS, as well as the data and potential roles of GLP-1 RAs in managing this condition.
多囊卵巢综合征（PCOS）是育龄期女性常见的内分泌紊乱疾病。这种病症与多种激素、生殖和代谢改变有关，包括雄激素过多、排卵障碍和高胰岛素血症状态。改善PCOS需要一种个性化的治疗方法，关注患者的主要问题，目标是解决卵巢功能障碍、减少高雄激素血症并改善代谢改变，特别是通过减轻体重来实现。胰高血糖素样肽-1受体类似物（GLP-1 RAs）这一治疗类别因其多种有益作用（如体重减轻），成为PCOS的一个有吸引力的选择。在本综述中，我们讨论了PCOS的临床和病理方面，以及GLP-1 RAs在管理这种病症中的数据和潜在作用。
